GOE-3450 |
NEURONTIN |
DM-1796 |
GABAPENTIN |
GRALISE |
CI-945 |
NEURONTIN® |
ACLONIUM |
GABAPENTINO |
GABAPENTINUM |
NOVO-GABAPENTINE |
2-[1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID |
GABAPENTIN GR |
GO 3450 |
GOE 3450 |
GABAPENTINE |
GOE 2450 |
1-(AMINOMETHYL)CYCLOHEXANEACETIC ACID |
GABAPENTINA |
GABAPETIN |
CI 945 |
chembl:CHEMBL940 |
chemidplus:60142-96-3 |
drugbank:00996 |
pubchem.compound:3446 |
rxcui:25480 |
Drug Indications | analgesic |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | for treatment of neuropathic pain |
Drug Class | anticonvulsants |
Year of Approval | 1993 |
Drug Class | analgesics |
inhibitor (inhibitory) |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
Trial Name | Depomed |
inhibitor (inhibitory) |
modulator |
Trial Name | Depomed |
Novel drug target | Established target |
Trial Name | gabapentin,N/ |
inhibitor (inhibitory) |
modulator |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Trial Name | Depomed |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
GABAPENTIN | Primary Drug Name |
Drug Class | analgesics |
Year of Approval | 1993 |
Drug Class | anticonvulsants |
Drug Indications | for treatment of neuropathic pain |
Drug Class | Small Molecule |
FDA Approval | approved |
C1108 | NCI drug code |
D0J0ZS | TTD Drug ID |